Skip to main content
. Author manuscript; available in PMC: 2010 Oct 14.
Published in final edited form as: Cancer Biol Ther. 2008 Sep 18;7(9):1326–1334. doi: 10.4161/cbt.7.9.6992

Figure 4.

Figure 4

MGMT silencing may be a useful mark for predicting the prognosis and efficacy of treatment of glioma patients treated with temozolomide. A) A diagram depicting different grades of gliomas highlighting both genetic and epigenetic changes that contribute to tumorigenesis. B) The silencing of MGMT, a protein involved in DNA repair, is associated with poor prognosis and may serve as a predictive factor for TMZ treatment.